BUENA, N.J. - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG) today announced that it has raised $6,500,000 through a private placement financing in which it sold common stock at $1.10 per share. Charles Moore, the Company’s CEO, commented that “We are happy to have completed this

(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG). IGI Laboratories, Inc. (the “Company”) is pleased to announce the appointment of Bhaskar Chaudhuri to its board of directors commencing December 1, 2010. Mr. Chaudhuri has more than 20 years experience in pharmaceutical management, research

BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented “This is a significant

BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG). On May 25, 2010, IGI received notice from the NYSE Amex staff indicating that the Company is below certain of the Exchange’s continued listing standards due to losses in five of its most recent fiscal years with equity below $6

BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, announced today that it has entered into a Turnkey Manufacturing Services agreement with The NeoStrata Company, headquartered in Princeton, NJ.

BUENA, N.J., May 3, 2016 / PRNewswire / -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Deutsche Bank 41 st  Annual Health Care Conference. The Conference will take place May 4-5,